<DOC>
	<DOCNO>NCT01820897</DOCNO>
	<brief_summary>Urinary tract infection ( UTI ) common complication kidney transplantation . Most series report incidence 20 50 % first year . In recent report center incidence 36.6 % first 6 month transplantation . The clinical consequence graft survival association immunological rejection well define . Nevertheless , association UTI high rate hospitalization cost widely recognize . There paucity trial , specially randomize control , compare antibiotic prophylaxis group patient . In recently publish metaanalysis Green et al . ( Transpl Infect Dis . 2011 Oct ; 13 ( 5 ) :441-7 ) find 6 clinical trial well design , conclusion antibiotic prophylaxis reduce incidence UTI risk sepsis . Based information , KDIGO guideline transplantation recommend prophylaxis UTI sulfamethoxazole-trimethoprim ( SMT ) . Nevertheless , rate bacterial resistance SMT report 50 % almost series . Fosfomycin-trometamol ( FT ) wall antibiotic ( piruvil-tranferase inhibitor ) show good bioavailability , especially urinary tract . It show wide antibacterial spectrum , important target seem enteric bacillus particularly Escherichia coli ( prevalent cause UTI ) . FT also show good activity E. coli producer Extended Spectrum Betalactamases . Recently , rate multi-drug resistant bacteria increase center evidence worldwide distribution . In addition , rate FT resistance stable last year ( &lt; 3 % ) . This phenomenon could explain property antibiotic , important one seem relate unique mechanism action lack propagate mechanism resistance least E. coli . There one clinical trial ( randomize control ) , compare FT placebo UTI prophylaxis ; 317 woman recurrent UTI ( three year ) include . They find rate 0.14 2.9 episodes/patient/year , respectively ( p &lt; 0.001 ) . Furthermore , FT resistance follow . Our hypothesis first six month kidney transplantation , UTI prophylaxis FT show great efficacy comparison SMT . Considering incidence UTI center ( 36.6 % ) rate UTI unique trial prophylaxis FT ( 14 % ) , 65 patient need group treatment demonstrate difference 22 % incidence UTI , power 80 % confidence level 95 % . The primary outcome incidence rate UTI first six month kidney transplantation . The secondary outcome , hospitalization rate , antibiotic resistance rate , rejection titer number de novo donor specific antibody . The investigator propose randomize , double blind , placebo control trial compare FT SMT efficacy safety prevent UTI first six month kidney transplantation . The investigator include patient two tertiary-care transplant center . Recruiting randomization carry separately center gender ( female patient great risk UTI ) . The medical visit schedule monthly include general laboratory , urine culture information gathering antibiotic side effect well adherence . Rejection rate number titer de novo donor specific antibody ( secondary outcome ) obtain accord standard care institutional kidney transplantation follow . These include kidney biopsy day 0 90 transplantation , well determination donor specific antibody sixth month follow . Graft biopsy also perform whenever graft dysfunction exist absence identifiable cause ( infection , urinary graft obstruction ) .</brief_summary>
	<brief_title>Efficacy Fosfomycin-Trometamol Urinary Tract Infection Prophylaxis After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Bacteriuria</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>Patients transplant National Institute medical Sciences Nutrition Salvador Zubiran National Institute Cardiology Ignacio Chavez Allergy Fosfomycinetrometamol Sulfamethoxazoletrimethoprim</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>